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ABSTRACT 
Background: The approval of novel targeted treatments for EGFR-positive and ALK-
positive non-small cell lung cancer (NSCLC) has led to the increased requirement for 
mutation testing.  
Results: We report our experience of ALK testing with immunohistochemistry (IHC) and 
fluorescence in-situ hybridization (FISH) and present the prevalence of EGFR, KRAS 
and ALK mutations. From January 2011 to May 2014, we found mutation rates of EGFR, 
KRAS and ALK to be 10.4% (67/643), 35.8% (86/240) and 2.3% (7/304) respectively. 
ALK-rearrangements were found to be associated with never smokers (p<0.001) and 
younger patients (≤50 years old) (p<0.001). ALK IHC protein expression in tumour cells 
is 100% sensitive (7 IHC+/7 FISH+) and 96.6% specific (113 IHC-/117 FISH-) for ALK-
rearrangements by FISH. ALK-rearranged tumours were wild-type for EGFR and KRAS.  
Conclusion: Our findings support the use of ALK protein expression and KRAS mutation 
testing as part of the molecular diagnostic algorithm for lung adenocarcinomas. 
Abstract word count: 148 
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INTRODUCTION 
Non-small cell lung cancer accounts for 87% of all lung cancers diagnosed in the UK (1). 
Lung adenocarcinomas can be further stratified according to the mutation status (2). 
Epidermal growth factor receptor (EGFR), Kirsten rat sarcoma 2 viral oncogene homolog 
(KRAS) and anaplastic lymphoma kinase (ALK) are currently the mutations most 
commonly tested for in lung adenocarcinomas. The stratification of lung 
adenocarcinomas according to these molecular subtypes has important clinical 
implications, informing the first-line treatment offered to each individual patient (2). 
Activating EGFR mutations were first described in 2004 as patients with mutations in 
EGFR gene were found to show clinical response to EGFR tyrosine kinase inhibitors 
(TKIs) (3). This discovery revolutionized the molecular diagnostic for lung cancer 
patients. Two of the most commonly occurring mutations, exon 19 deletions and exon 21 
L858R missense mutations confer sensitivity to EGFR TKIs (3). In contrast, exon 20 
T790M mutations are associated with resistance to EGFR TKIs (4). 
The identification of echinoderm microtubule-associated protein-like 4 anaplastic 
lymphoma kinase (EML4-ALK) fusion gene in a subgroup of NSCLC (5) as an 
oncogenic driver has led to the development of ALK inhibitors that show a dramatic and 
long-lived response in ALK-translocated tumours (6). ALK abnormalities are typically 
associated with younger age and never smokers (7). KRAS mutations in NSCLC occur 
more frequently in Caucasian populations and are associated with smoking (8). G12C and 
G12V subtypes are commonly found in patients with a smoking history whereas G12D is 
more likely to be found in non-smokers (9).   
The aim of this study was to evaluate the utility of ALK immunohistochemistry (IHC) 
and fluorescence in-situ hybridization (FISH) and to determine the prevalence of EGFR, 
KRAS and ALK mutations. 
 4 
METHODS  
Specimens, demographics and clinical information 
From January 2011 to May 2014, a total of 682 cases in SE Scotland were tested for the 
presence of EGFR, KRAS mutations and/or ALK rearrangements. This comprised 586 
adenocarcinomas, 75 non-small cell lung carcinomas and 21 other tumours (including 6 
cases of large cell neuroendocrine carcinoma, 4 cases of squamous cell carcinoma, 3 
cases of large cell undifferentiated carcinoma, 2 mixed adenosquamous carcinoma, 1 case 
each of mixed squamous and large cell neuroendocrine carcinoma, carcinoid tumour, 
pleomorphic carcinoma, sarcoma, sarcomatoid carcinoma and mixed malignant 
peripheral nerve sheath tumour and large cell neuroendocrine carcinoma). Common to 
these 21 other tumours was young age and/or a history of non-smoking which was 
deemed by the oncologist as a reason for molecular testing. Of these 37 samples were 
insufficient due to low volume of tumour or tissue. In January 2013, KRAS mutation 
testing was introduced and was carried out on 242 cases. ALK rearrangement testing was 
introduced in 2012 and carried out on 304 cases. Most of these samples were biopsy 
specimens, 428 followed by 160 cell blocks (prepared from cytological specimens such 
as EBUS aspirates or pleural fluids), and 94 surgically resected samples either from the 
primary tumour or site of metastasis. Clinical data and demographics of all patients were 
collected retrospectively from electronic clinical records. This study was conducted as 
part of an audit on the clinical testing services for lung adenocarcinomas in molecular 
pathology. Lung cancer staging was done in accordance with the 7th Edition “TNM 
classification of malignant tumours” (10). Smoking status was classified as never 
smokers (<100 cigarettes in lifetime), former smokers (stopped smoking for at least one 
year before diagnosis) and current smokers (including those who stopped smoking less 
than one year prior to diagnosis) (9). Smoking exposure was measured in pack years 
whereby one pack year was defined as smoking 20 cigarettes per day in one year. 
ALK, EGFR and KRAS mutation testing 
ALK IHC was carried out using the D5F3 clone (Cell Signaling Technology) to identify 
expression of the abnormal ALK fusion protein. The scoring criteria used was based on a 
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binary scoring system positive of negative ALK status. Positive staining constitutes any 
cytoplasmic and/or nuclear staining. An equivocal pattern of staining was used for cases 
showing apical or focal membranous staining and for these cases FISH analysis was 
requested to determine the ALK rearrangement status. The tumours showing ALK 
positivity were also further tested by fluorescence in-situ hybridization (FISH). FISH 
analysis was performed using the Vysis LSI ALK Break Apart Rearrangement Probe 
from Abbott Molecular (UK) and the evaluation was carried out as recommended by the 
manufacturer.  
The EGFR and KRAS mutation status was determined using DNA extracted from 
formalin-fixed, paraffin embedded sections. Macrodissection was carried out on a large 
number of cases to enrich the tumour DNA. The amount of tissue used varied from 3 to 6 
10µm thick sections depending on the amount of tumour tissue present in each case. 
DNA was analysed for 29 EGFR mutations using the Qiagen's therascreen® EGFR RGQ 
PCR method. KRAS testing was carried out using an in-house pyrosequencing method to 
detect mutations in codons 12, 13 and 61 of the KRAS oncogene using the primer 
sequences described (please see Supporting Information).  
Statistical Analysis 
Data were analysed using χ2 test for association and trend (where categories were ordered, 
eg smoking). Where expected observations were less than 5, Fisher’s Exact test was 
employed. Multivariable explanatory models were analysed using logistic regression. 
RESULTS 
Of 682 patients with lung cancer included 680 were tested for EGFR mutations, 304 for 
ALK and 242 for KRAS mutations concomitantly.  
Of 304 cases tested for the presence of and ALK abnormality by IHC, 9 were positive 
(2.9%), 3 were equivocal (1%) and 292 (96.1%) were negative. Of these, 125 cases were 
also analysed by FISH. Out of the 9 IHC positive cases, 7 cases were confirmed by FISH 
as showing an ALK gene rearrangement, 1 case showed a definite ALK IHC positive 
staining but FISH analysis showed no evidence of an ALK rearrangement and 1 case 
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failed to hybridise. The 3 cases with an equivocal ALK IHC pattern showed no ALK 
gene rearrangement by FISH. Taken as a whole, ALK IHC+/FISH+ was found in 2.3% of 
the cases in our study. We report 100% sensitivity (7 IHC+/7 FISH+) and 96.6% 
specificity (113 IHC-/117 FISH-) when comparing results of ALK protein IHC 
expression with ALK FISH analysis. In our cohort, ALK rearrangements were found to 
be associated with never smokers (p<0.001) and younger patients (≤50 years old) 
(p<0.001).  
Table 1 summarises the results for EGFR, KRAS mutations and ALK rearrangement with 
demographical and clinical characteristics. Cases with insufficient material for analysis 
were excluded from the statistical analysis. None of the cases in our cohort had 
concomitant mutations of EGFR, KRAS or ALK translocation, supporting the 
adenocarcinoma oncogenome pattern of molecular exclusivity (11). 
EGFR mutations show a slight female predominance with 345 females (53.7%) and 298 
males (46.3%). 14.5% of females and 5.7% of males had EGFR mutation in their tumours, 
with a prevalence of 10.4% (n=67) EGFR mutations in our cohort. Deletions in exon 19 
(24/67) and L858R exon 21 mutation (32/67) are the two most prevalent mutations as 
shown in Table 2. In 3 cases a double mutation of EGFR gene was present, including two 
cases of L858R exon 21 and T790M exon 20 mutations, and one case of L861Q exon 21 
and exon 18 mutations. Of note, in our cohort, two cases of a rare deletion and insertion 
in exon 19 were also reported.  
EGFR mutations were found in 35.1% (27/77) of never smokers, 9.3% (23/247) of 
former smokers and 5.0% (14/280) of current smokers. There was a significant 
association between EGFR-mutant tumours and never smoking status (p<0.001). There is 
evidence to suggest a linear association with smoking history as increasing duration of 
smoking is associated with a decreasing proportion of EGFR mutations (p<0.001). 
Females had a significant increased likelihood of EGFR mutation compared to males (OR 
2.80, 95% CI 1.59-4.97, p<0.001). However, this effect was lost when smoking pack-
years were taken into account. An increase in one pack years of smoking resulted in a 
decrease in the odds ratio of EGFR mutations (OR 0.94, 95% CI 0.92 - 0.96, p<0.001). 
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KRAS mutations were found in 35.8% (86/240) of cases successfully tested. The most 
frequent mutation found was in codon 12 with 74 cases (86%) followed by 7 cases with 
codon 61 mutations (8.1%) and 5 cases with mutations in codon 13 (5.8%), as shown in 
Figure 1. KRAS-mutation status was associated with a history of smoking, in both former 
(OR 6.26, 95% CI 2.00-19.56, p=0.002) and current smokers (OR 6.82, 95% CI 2.18-
21.35, p=0.001) significantly higher than in non-smokers. Neither gender (p=0.09) nor 
the number of smoking pack years (p=0.13) had an influence on the rates of KRAS 
mutations.  The frequency of EGFR and KRAS mutations by smoking status is illustrated 
in Figure 2.   
DISCUSSION 
The approval of EGFR and ALK TKIs for use in subsets of patients with activating 
mutations means there is a requirement to provide a molecular pathology service capable 
of multiplex testing in a cost-effective manner. As these mutations tend to be mutually 
exclusive (12), we have introduced KRAS testing as a tool to help select patients for 
ALK testing and at the same time enable a wise use of the budget. KRAS testing offers a 
more cost-effective and clinically useful alternative compared to ALK FISH testing (13). 
Moreover, despite not being linked to predicting a direct response to therapy,  there is 
strong evidence that KRAS mutations are involved in the mechanism of resistance to 
crizotinib (14) and in addition, KRAS mutations act as a stronger predictor of response to 
EGFR TKI therapy than the EGFR mutation status alone (15).  Therefore, based on the 
reasons above, our testing algorithm for NSCLC testing includes EGFR, ALK IHC 
and/or FISH and KRAS mutations testing (13).  
Our study reports the prevalence of EGFR, ALK and KRAS mutations in South East of 
Scotland as 10.4%, 2.3% and 35.8% respectively.  
There is large variation in the prevalence of ALK abnormalities as highlighted in a large 
systematic review (7). This variation in reporting is due to the selection criteria, with 
some studies including squamous cell carcinomas in their testing algorithms. There is not 
much data published from UK based population studies but data presented at local or 
national meetings describes the actual prevalence of ALK rearrangement in lung NSCLC 
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in the UK to be lower than initially reported at approximately 1 to 2% (unpublished data). 
Although ALK rearrangements are mutually exclusive with EGFR and KRAS mutations 
in our cohort, small numbers of tumours with concomitant ALK and EGFR or ALK and 
KRAS mutations have been reported in the literature (16). In our cohort six out of the 
seven ALK rearranged tumours were non-smokers, only one patient was identified to be a 
smoker.  
We have not identified any false negative IHC negative / FISH positive cases and this 
could be due to the relative small numbers in out cohort. Other studies report a 
discrepancy rate of up to 24% possibly due to hierarchical screening (17). While the 
method commonly used to detect ALK abnormalities is FISH, most labs are now 
adopting immunohistochemistry as a screen test followed by confirmatory FISH (18). 
This is cost-effective and offers a quicker turn-around time. More importantly, a recent 
study argues that the detection of the ALK fusion protein by immunohistochemistry is 
superior to an ALK FISH test in predicting tumour response and survival to crizotinib 
(19). In view of this new data and our own experience, molecular testing of lung NSCLC 
should include ALK immunohistochemistry either as a screening tool or perhaps as a 
primary diagnostic test to detect ALK rearrangements.  
Variable EGFR mutation rates have been reported across the world. One study in a single 
centre in the US reported an EGFR mutation rate of 20%, while a European study 
reported EGFR mutation rate of as low as 4.9% in an unselected cohort of patients 
whereby all newly diagnosed NSCLC cases were screened for EGFR mutations (20). 
Data from Asian populations generally report higher mutation rates, in some studies as 
high as 66.3% (21). One likely explanation for the higher prevalence reported in most 
studies, including our study, was the possible selection bias when referring cases for 
mutation testing. At the early stages of EGFR mutation testing services, undoubtedly 
most of the cases referred seemed likely to be selected on the basis of never smoking 
status and younger age.  
Our study highlights the association of female gender and never smoking status with the 
presence of EGFR mutations. Among the non-smokers tested, 74.6% were female. 
Despite the association found between the non-smoking status and the presence of EGFR 
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mutations, we do not recommend using smoking status as a selection criterion for 
excluding smokers from EGFR testing. As demonstrated, EGFR mutations are also 
present in smokers and former smokers, although to a much lesser degree.  
We demonstrate that in smokers with any smoking history, there is a significant 
association with an increased likelihood of KRAS mutations regardless of smoking pack 
years. 
In conclusion, ALK protein expression in tumour cells is 100% sensitive and 96.6% 
specific for ALK rearrangements by FISH. Our findings support the use of ALK IHC as 
an effective screening tool for this rare but clinically important molecular subgroup of 
lung adenocarcinomas.  
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Table 1. Frequency of patients tested for EGFR, KRAS and ALK and their 
demographical and clinical characteristics. 
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Table 2. EGFR mutations detected in our cohort. 
 
 
 
Figure Legends 
Figure 1: KRAS mutations detected in our cohort. 
Figure 2: Frequency of EGFR and KRAS mutations according to smoking history.  
 
Supporting Information 
KRAS primers sequences: forward 5’-GGCCTGCTGAAAATGACTG -3’ and reverse 
5’-Biotin-GCTGTATCGTCAAGGCACTCT-3’ for KRAS codons 12 and 13, forward 
5’-Biotin-TGGAGAAACCTGTCTCTTGGATAT-3’ and reverse 5’-
CTGGTCCCTCATTGCACTGTACTC-3’ for KRAS codon 61.  
EGFR mutation Frequency (%) 
L858R exon 21   32 (47.8%) 
Deletion in exon 19 24 (35.8%) 
Mutation in exon 18 3 (4.5%) 
Insertion in exon 20 2 (3.0%) 
L861Q exon 21 1 (1.5%) 
L858R exon 21 & T790M exon 20 2 (3.0%) 
Deletion and insertion in exon 19 2 (3.0%) 
L861Q exon 21 & mutation in exon 18 1 (1.5%) 
Total 67  
